Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.
Hartmann
Jörg Thomas
JT
Kanz
Lothar
L
D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D006200:Hair Color / Q000187:drug effects*; D006801:Humans; D017496:Hypopigmentation / Q000139:chemically induced* / Q000503:physiopathology; D007082:Ileum / Q000473:pathology; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007414:Intestinal Neoplasms / Q000235:genetics / Q000628:therapy; D007889:Leiomyoma / Q000235:genetics / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010507:Periodicity; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects* / Q000378:metabolism; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D000077210:Sunitinib; D014430:Twins, Monozygotic
D007211:Indoles; D011758:Pyrroles; D019009:Proto-Oncogene Proteins c-kit; D000077210:Sunitinib